The Cystic Fibrosis Foundation today applauds the Food and Drug Administration's approval of Kalydeco™ (ivacaftor; previously known as VX-770), a major advance in the search for a cure for cystic fibrosis.
Site Search
Showing 71 - 80 of 119 results
News
|
Dec. 21, 2012
|
2 min read
News
|
Jan. 31, 2012
|
3 min read
A $7.5 million research award will go to Southern Research to identify potential new drugs for people with rare CF mutations, known as nonsense mutations, Cystic Fibrosis Foundation Therapeutics Inc. announced today.
News
|
Oct. 21, 2015
|
2 min read
The Cystic Fibrosis Foundation celebrates the FDA's approval today of the lumacaftor/ivacaftor combination drug (Orkambi™) as an important advance for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation.
News
|
July 2, 2015
|
4 min read
Press Release
|
March 18, 2015
|
3 min read
An observation by surfers in Australia has led to a simple, inexpensive hypertonic saline therapy.
News
|
Jan. 18, 2006
|
3 min read
News
|
Aug. 11, 2014
|
1 min read
News
|
Feb. 28, 2007
|
2 min read